Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: RE: ease, re: Contigency Basis.....

RE: ease, re: Contigency Basis.....

posted on Jan 16, 2005 10:36AM
ease,

You are wrong about the 50 million in debt issue. As Brian said, PTSC has accumulated losses of 50 million, which is the accumulated deficit that you are seeing. Your disconnect comes in because you naturally assume if you lost 50 million, you must owe 50 million. That`s where equity comes in (in this case issuance of stock, warrants, debentures, etc.) In a nutshell PTSC has funded the 50 million in losses by issuing equity, not debt. Big difference, of course, is that debt has to be paid back to someone, equity not necessarily so.

You`re arguing with the 2 most astute posters here( ronran and biajj). Instead of telling them to do a little more research, I suggest you might do exactly that. They`ve been with this stock for 5 or so years. It`s unlikely you are going to be telling them anything that they are not already aware of.

Share
New Message
Please login to post a reply